EFFECTIVE SURGICAL ADJUVANT THERAPY FOR HIGH-RISK RECTAL-CARCINOMA

被引:1495
作者
KROOK, JE
MOERTEL, CG
GUNDERSON, LL
WIEAND, HS
COLLINS, RT
BEART, RW
KUBISTA, TP
POON, MA
MEYERS, WC
MAILLIARD, JA
TWITO, DI
MORTON, RF
VEEDER, MH
WITZIG, TE
CHA, S
VIDYARTHI, SC
机构
[1] MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA
[2] DULUTH COMMUNITY CLIN ONCOL PROGRAM, DULUTH, MN USA
[3] MAYO CLIN, SCOTTSDALE, AZ USA
[4] BILLINGS CLIN, BILLINGS, MT USA
[5] IOWA ONCOL RES ASSOC, COMMUNITY CLIN ONCOL PROGRAM, DES MOINES, IA USA
[6] ILLINOIS ONCOL RES ASSOC, COMMUNITY CLIN ONCOL PROGRAM, PEORIA, IL USA
[7] CREIGHTON UNIV, NEBRASKA ONCOL GRP, OMAHA, NE 68178 USA
[8] SASKATCHEWAN CANC FDN, REGINA, SASKATCHEWAN, CANADA
[9] UNIV NEBRASKA, MED CTR, OMAHA, NE 68105 USA
[10] DUKE UNIV, MED CTR, DURHAM, NC 27710 USA
关键词
D O I
10.1056/NEJM199103143241101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Radiation therapy as an adjunct to surgery for rectal cancer has been shown to reduce local recurrence but has not improved survival. In a previous study, combined radiation and chemotherapy improved survival significantly as compared with surgery alone, but not as compared with adjuvant radiation, which many regard as standard therapy. We designed a combination regimen to optimize the contribution of chemotherapy, decrease recurrence, and improve survival as compared with adjuvant radiation alone. Methods. Two hundred four patients with rectal carcinoma that was either deeply invasive or metastatic to regional lymph nodes were randomly assigned to postoperative radiation alone (4500 to 5040 cGy) or to radiation plus fluorouracil, which was both preceded and followed by a cycle of systemic therapy with fluorouracil plus semustine (methyl-CCNU). Results. After a median follow-up of more than seven years, the combined therapy had reduced the recurrence of rectal cancer by 34 percent (P = 0.0016; 95 percent confidence interval, 12 to 50 percent). Initial local recurrence was reduced by 46 percent (P = 0.036; 95 percent confidence interval, 2 to 70 percent), and distant metastasis by 37 percent (P = 0.011; 95 percent confidence interval, 9 to 57 percent). In addition, combined therapy reduced the rate of cancer-related deaths by 36 percent (P = 0.0071; 95 percent confidence interval, 14 to 53 percent) and the overall death rate by 29 percent (P = 0.025; 95 percent confidence interval, 7 to 45 percent). Its acute toxic effects included nausea, vomiting, diarrhea, leukopenia, and thrombocytopenia. These effects were seldom severs. Severe, delayed treatment-related reactions, usually small-bowel obstruction requiring surgery, occurred in 6.7 percent of all patients receiving radiation, and the frequencies of these complications were comparable in both treatment groups. Conclusions. The combination of postoperative local therapy with radiation plus fluorouracil and systemic therapy with a fluorouracil-based regimen significantly and substantively improves the results of therapy for rectal carcinoma with a poor prognosis, as compared with postoperative radiation alone.
引用
收藏
页码:709 / 715
页数:7
相关论文
共 31 条
[1]  
[Anonymous], 1985, NEW ENGL J MED, V312, P1465
[2]  
BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO
[3]  
2-Q
[4]   LEUKEMIA AND PRELEUKEMIA AFTER ADJUVANT TREATMENT OF GASTROINTESTINAL CANCER WITH SEMUSTINE (METHYL-CCNU) [J].
BOICE, JD ;
GREENE, MH ;
KILLEN, JY ;
ELLENBERG, SS ;
KEEHN, RJ ;
MCFADDEN, E ;
CHEN, TT ;
FRAUMENI, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (18) :1079-1084
[5]   CANCER STATISTICS, 1991 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) :19-36
[6]   PHARMACOLOGIC REQUIREMENTS FOR OBTAINING SENSITIZATION OF HUMAN-TUMOR CELLS-INVITRO TO COMBINED 5-FLUOROURACIL OR FTORAFUR AND X-RAYS [J].
BYFIELD, JE ;
CALABROJONES, P ;
KLISAK, I ;
KULHANIAN, F .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (11) :1923-1933
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294
[9]   POSTOPERATIVE ADJUVANT CHEMOTHERAPY OR RADIATION-THERAPY FOR RECTAL-CANCER - RESULTS FROM NSABP PROTOCOL R-01 [J].
FISHER, B ;
WOLMARK, N ;
ROCKETTE, H ;
REDMOND, C ;
DEUTSCH, M ;
WICKERHAM, DL ;
FISHER, ER ;
CAPLAN, R ;
JONES, J ;
LERNER, H ;
GORDON, P ;
FELDMAN, M ;
CRUZ, A ;
LEGAULTPOISSON, S ;
WEXLER, M ;
LAWRENCE, W ;
ROBIDOUX, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (01) :21-29
[10]   PREOPERATIVE RADIOTHERAPY AS ADJUVANT TREATMENT IN RECTAL-CANCER - FINAL RESULTS OF A RANDOMIZED STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) [J].
GERARD, A ;
BUYSE, M ;
NORDLINGER, B ;
LOYGUE, J ;
PENE, F ;
KEMPF, P ;
BOSSET, JF ;
GIGNOUX, M ;
ARNAUD, JP ;
DESAIVE, C ;
DUEZ, N .
ANNALS OF SURGERY, 1988, 208 (05) :606-614